Vertex reports Phase 3 win for kidney drug, will seek FDA approvalnews2026-03-10T15:20:08+00:00March 10th, 2026|Endpoints News|
Ascletis touts GLP-1 quarterly dosing data; Mineralys apnea Phase 2 missesnews2026-03-10T15:02:46+00:00March 10th, 2026|Endpoints News|
China is going after the world’s most expensive drugs: Endpoints Signalnews2026-03-10T13:00:49+00:00March 10th, 2026|Endpoints News|
FDA widens use of leucovorin without new trial datanews2026-03-10T13:00:12+00:00March 10th, 2026|Endpoints News|
Breakout Ventures closes $114M fund, plans 20 investmentsnews2026-03-10T11:00:55+00:00March 10th, 2026|Endpoints News|
BioNTech co-founders to exit company and start a new onenews2026-03-10T10:30:30+00:00March 10th, 2026|Endpoints News|
Ipsen pulls cancer drug Tazverik from market over safety risksnews2026-03-09T18:16:40+00:00March 9th, 2026|Endpoints News|
What Prasad’s exit means for the FDA moving forwardnews2026-03-09T17:51:46+00:00March 9th, 2026|Endpoints News|
Universal Health Services buys Talkspace for $835Mnews2026-03-09T15:37:23+00:00March 9th, 2026|Endpoints News|
